An estimated 3.6 million Medicare beneficiaries could potentially access Wegovy now that the Food and Drug Administration (FDA) approved the drug for reducing the risk of incidents related to cardiovascular disease. A KFF analysis found that among the 13.7 million people on Medicare diagnosed with obesity, 3.6 million, or roughly 1 in 4, of these…
With an increasing emphasis on cutting-edge therapies and interventions to address the rising incidence of obesity globally, the global obesity market is a sizable industry.